The stem cell transplant program in Pakistan--the first decade

Area of Science:

• Hematology
• Transplant Medicine
• Oncology

Background:

• Stem cell transplantation (SCT) is a life-saving treatment for various hematological diseases.
• SCT services in Pakistan commenced in 1995, with significant growth in allogeneic bone marrow transplantation (BMT) since 1999.
• Key indications include aplastic anemia, beta-thalassemia major, and hematological malignancies.

Purpose of the Study:

• To review the development and current status of stem cell transplantation in Pakistan.
• To highlight the unique characteristics and challenges of SCT in the Pakistani context.
• To assess the early outcomes and survival rates of SCT procedures.

Main Methods:

• Retrospective analysis of SCT procedures performed in Pakistan.
• Review of transplant indications, donor types, and patient characteristics.
• Evaluation of transplant-related mortality and long-term survival rates.

Main Results:

• Over 350 allogeneic SCTs and 50 autologous SCTs have been performed across multiple centers.
• Majority of transplants are allogeneic, with HLA-identical sibling donors used in 70% of cases.
• Promising survival rates: 78% (aplastic anemia), 72% (beta-thalassemia major), 49% (leukemia); with 10-20% transplant-related mortality.

Conclusions:

• SCT in Pakistan has shown promising early results despite facing significant financial and infrastructural hurdles.
• Unique challenges include a high prevalence of CMV-positive donor-recipient pairs and specific infectious disease concerns (fungal infections, TB, malaria).
• Sustained growth and wider accessibility of SCT necessitate increased government support, improved infrastructure, and human resource development.